Colorectal Cancer Screening Market (2026-2036)

The colorectal cancer screening market covers faecal immunochemical and guaiac faecal occult blood tests, multi-target stool DNA and stool RNA tests, and blood-based biomarker tests, together with the collection kits, reagents and laboratory services supplied with them. The growth of this market is driven by a blood test approved for primary screening, by a numeric Medicare coverage floor that defines what qualifies, by the screening age having been lowered to 45, and by organised population programmes expanding outside North America.

The FDA approved the Shield blood-based test from Guardant Health, Inc. on 29 July 2024 for screening for colorectal cancer in adults aged 45 years and older at average risk for the disease, reporting 83% sensitivity for colorectal cancer and 90% specificity for advanced neoplasia in the ECLIPSE registrational study of more than 20,000 patients. National coverage determination 210.3 covers faecal occult blood testing by guaiac or immunoassay in beneficiaries aged 45 and older once every 12 months, multi-target stool DNA testing in beneficiaries aged 45 to 85 once every three years, and a blood-based biomarker test in beneficiaries aged 45 to 85 once every three years, in each case for asymptomatic beneficiaries at average risk. A blood-based biomarker test must be performed in a laboratory certified under the Clinical Laboratory Improvement Amendments, ordered by a treating physician, and hold FDA market authorisation with an indication for colorectal cancer screening, achieving a minimum sensitivity of 74% and a minimum specificity of 90% for detecting colorectal cancer against colonoscopy in the pivotal studies contained in the FDA labelling. A sensitivity of 83% therefore clears the coverage floor by nine percentage points, so the blood route is both approved and reimbursed under Medicare.

The United States Preventive Services Task Force recommendation dated 18 May 2021 gives screening in adults aged 50 to 75 a grade A, screening in adults aged 45 to 49 a grade B, and selective screening in adults aged 76 to 85 a grade C, listing high-sensitivity guaiac faecal occult blood testing or faecal immunochemical testing every year, stool DNA with faecal immunochemical testing every one to three years, computed tomography colonography every five years, flexible sigmoidoscopy every five years, flexible sigmoidoscopy every ten years with annual faecal immunochemical testing, and colonoscopy every ten years. A blood-based test does not appear among those strategies, so a test that Medicare covers under a defined numeric standard sits outside the task force menu, and commercial coverage without cost sharing under preventive services provisions does not follow automatically. The blood segment therefore grows through Medicare and self-pay before it grows through employer-sponsored insurance.

Colorectal cancer develops from precancerous polyps over years, which makes it one of the few cancers in which screening can prevent the disease rather than only detect it earlier. Removing an advanced adenoma at colonoscopy prevents a cancer that would otherwise have formed, and most of the mortality reduction attributed to screening comes from that prevention rather than from earlier diagnosis of established cancer. The relative value of a screening test therefore depends on how well it detects precancerous lesions as well as how well it detects cancer.

The United States Preventive Services Task Force recommendation dated 18 May 2021 gives screening in adults aged 50 to 75 a grade A, screening in adults aged 45 to 49 a grade B, and selective screening in adults aged 76 to 85 a grade C, listing high-sensitivity guaiac faecal occult blood testing or faecal immunochemical testing every year, stool DNA with faecal immunochemical testing every one to three years, computed tomography colonography every five years, flexible sigmoidoscopy every five years, flexible sigmoidoscopy every ten years with annual faecal immunochemical testing, and colonoscopy every ten years. The strategies differ in interval as much as in per-test performance, so annual faecal immunochemical testing and colonoscopy every ten years are both recommended despite a very large difference in single-test sensitivity, because programmatic detection over a decade depends on repetition as well as on accuracy.

National coverage determination 210.3 covers faecal occult blood testing by guaiac or immunoassay in beneficiaries aged 45 and older once every 12 months, multi-target stool DNA testing in beneficiaries aged 45 to 85 once every three years, and a blood-based biomarker test in beneficiaries aged 45 to 85 once every three years, in each case for asymptomatic beneficiaries at average risk. A blood-based biomarker test must be performed in a laboratory certified under the Clinical Laboratory Improvement Amendments, ordered by a treating physician, and hold FDA market authorisation with an indication for colorectal cancer screening, achieving a minimum sensitivity of 74% and a minimum specificity of 90% for detecting colorectal cancer against colonoscopy in the pivotal studies contained in the FDA labelling. The coverage threshold is expressed for detection of colorectal cancer against colonoscopy and not for detection of advanced adenomas, which is the measure that matters for prevention, so a test can qualify for coverage while contributing little to the prevention of cancers that have not yet formed.

The FDA approved the Shield blood-based test from Guardant Health, Inc. on 29 July 2024 for screening for colorectal cancer in adults aged 45 years and older at average risk for the disease, reporting 83% sensitivity for colorectal cancer and 90% specificity for advanced neoplasia in the ECLIPSE registrational study of more than 20,000 patients. Approval of a blood test for primary screening rather than for use after a positive stool test established a third sample type in this market, and the reported specificity figure of 90% was given for advanced neoplasia while the sensitivity figure of 83% was given for colorectal cancer, which are different measures and should not be read as a single performance pair.

A blood-based test does not appear among the task force strategies, so its coverage position differs between Medicare and commercial insurance, since a grade A or B recommendation is what obliges non-grandfathered commercial plans to cover a preventive service without cost sharing. Medicare covers the blood route under its own numeric standard regardless, and the gap between the two determines where blood testing volume can arise in the near term.

A substantial share of the eligible population is not screened by any method, because colonoscopy requires bowel preparation, sedation, time away from work and an accompanying adult, and stool testing requires handling a sample at home and returning it. A blood draw taken during a routine appointment removes each of those obstacles, which is why a test with lower sensitivity can produce more detected cancers across a population than a better test that fewer people complete.

A programme that moves people from colonoscopy to blood testing gains participation and loses polypectomy, because a blood test identifies cancer rather than removing the lesion that would become one, and the mortality benefit of screening rests substantially on that removal. A blood test used to reach people who would otherwise do nothing adds benefit, while a blood test used instead of colonoscopy by people who would have attended may not.

Medicare covers a blood-based test once every three years and multi-target stool DNA once every three years, while faecal occult blood testing is covered annually, so a test with higher single-test sensitivity performed every three years may detect no more over a decade than a weaker test performed every year. Comparisons of per-test sensitivity between these options are therefore misleading unless the interval is held constant.

Lowering the recommended starting age to 45 added a cohort to the eligible population that has the highest proportional increase in incidence and the lowest screening participation, since people in their late forties have no established habit of preventive testing and often no regular physician. That cohort is the fastest-growing segment in this market and the one for which a convenient test has the greatest marginal effect. Reaching it also establishes a testing habit that produces repeat revenue across the following three decades, which makes the cohort worth more than its current volume implies. Clinician awareness in that age band remains the weak point, since many practices still prompt screening from 50 in their systems rather than from 45.

Follow-on colonoscopy after a positive non-invasive test is the cost that determines a programme economics, since a test with 90% specificity sends one in ten unaffected people for a procedure, and the volume of those procedures rather than the price of the test governs total expenditure. Payers assessing a new non-invasive test therefore examine its specificity and the resulting colonoscopy burden more closely than its sensitivity. A programme raising participation also raises that burden proportionally, so the two decisions cannot be taken separately and an endoscopy service has to be expanded alongside any outreach effort.